{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:39Z","timestamp":1790660739564,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI179699"],"award-info":[{"award-number":["UM1 AI179699"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TB Alliance"},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["TRIA2015-1102"],"award-info":[{"award-number":["TRIA2015-1102"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["03ZZ0803A"],"award-info":[{"award-number":["03ZZ0803A"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["03ZZ0835A"],"award-info":[{"award-number":["03ZZ0835A"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"publisher","award":["03ZZ0826A"],"award-info":[{"award-number":["03ZZ0826A"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry for Education and Research","award":["01KA1701"],"award-info":[{"award-number":["01KA1701"]}]},{"DOI":"10.13039\/501100021711","name":"Bavarian Ministry for Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"and the Arts"},{"name":"Swiss State Secretariat for Education, Research, and Innovation"},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>BTZ-043 is a promising novel drug candidate for antituberculosis treatment. This study aimed to apply a previously developed mouse-to-human translational modeling platform for antituberculosis drugs to predict phase 2A outcomes for BTZ-043 in humans and evaluate the impact of observed drug-drug interactions on the contribution of BTZ-043 to combotherapy in a mouse model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study utilized data from mouse experiments for BTZ-043 monotherapy and combotherapy with bedaquiline, pretomanid, and linezolid, and clinical information for BTZ-043 monotherapy. The translational models were applied to predict the colony-forming units as a measure of efficacy in humans treated with BTZ-043 monotherapy and evaluate the effect of BTZ-043 on the pharmacokinetics-pharmacodynamics of combotherapy bedaquiline, pretomanid, and linezolid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mouse-pharmacokinetic and mouse-pharmacodynamic data for BTZ-043 monotherapy were best described by 2-compartmental and direct Emax models, respectively. The model-based prediction of efficacy in humans was comparable to the observed phase 2A efficacy. Single-compartmental models, developed separately, best described the mouse-pharmacokinetic data for bedaquiline, pretomanid, and linezolid in combotherapy. Coadministration with BTZ-043 was associated with at least a 2-fold reduction in bedaquiline, pretomanid, and linezolid exposures in mice, and model-based simulations suggested that the observed decreases in exposure to these drugs would have resulted in even lower efficacy than what was observed when bedaquiline, pretomanid, and linezolid are coadministered with BTZ-043.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The translational modeling platform adequately predicted the efficacy of BTZ-043 monotherapy. In the absence of drug-drug interactions, coadministration of BTZ-043 with bedaquiline, pretomanid, and linezolid in combotherapy is predicted to improve treatment efficacy.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. NCT0404400.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf088","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T07:36:22Z","timestamp":1739777782000},"page":"e901-e911","source":"Crossref","is-referenced-by-count":3,"title":["Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models"],"prefix":"10.1093","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-5954","authenticated-orcid":false,"given":"Bernard","family":"Ngara","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-0954","authenticated-orcid":false,"given":"Lorenzo","family":"Flori","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California , San Francisco, California ,","place":["USA"]},{"name":"Department of Pharmacy, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7247-1360","authenticated-orcid":false,"given":"Rob Christiaan","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-7287","authenticated-orcid":false,"given":"Jacqueline P","family":"Ernest","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6066-5392","authenticated-orcid":false,"given":"Sandeep","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9727-9334","authenticated-orcid":false,"given":"Heena","family":"Soni","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"H\u00f6lscher","sequence":"additional","affiliation":[{"name":"Division of Infection Immunology, Research Center Borstel-Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"Thematic Translational Unit Tuberculosis, German Center for Infection Research, Partner Site Hamburg-L\u00fcbeck-Borstel-Riems , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7883-4433","authenticated-orcid":false,"given":"Kerstin","family":"Walter","sequence":"additional","affiliation":[{"name":"Division of Infection Immunology, Research Center Borstel-Leibniz Lung Center , Borstel ,","place":["Germany"]},{"name":"Thematic Translational Unit Tuberculosis, German Center for Infection Research, Partner Site Hamburg-L\u00fcbeck-Borstel-Riems , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-9857","authenticated-orcid":false,"given":"Julia","family":"Dreisbach","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases and Tropical Medicine, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich , Munich ,","place":["Germany"]},{"name":"German Center for Infection Research, partner site Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6937-8330","authenticated-orcid":false,"given":"Michael","family":"Hoelscher","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases and Tropical Medicine, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich , Munich ,","place":["Germany"]},{"name":"German Center for Infection Research, partner site Munich , Munich ,","place":["Germany"]},{"name":"Immunology, Infection and Pandemic Research, Fraunhofer Institute for Translational Medicine and Pharmacology , Munich ,","place":["Germany"]},{"name":"Unit Global Health, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health , Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric L","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Radojka M","family":"Savic","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, California ,","place":["USA"]},{"name":"Center for Tuberculosis, University of California , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025060208124625800_jiaf088-B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-2600(19)30418-7","article-title":"WHO global progress report on tuberculosis elimination","volume":"8","author":"Harding","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025060208124625800_jiaf088-B2","author":"World Health Organization"},{"key":"2025060208124625800_jiaf088-B3","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Medicine"},{"key":"2025060208124625800_jiaf088-B4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB Treatment\u20132017","year":"2018","journal-title":"Lancet"},{"key":"2025060208124625800_jiaf088-B5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025060208124625800_jiaf088-B6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2025060208124625800_jiaf088-B7","doi-asserted-by":"crossref","first-page":"100285","DOI":"10.1016\/j.jctube.2021.100285","article-title":"The pipeline of new molecules and regimens against drug-resistant tuberculosis","volume":"25","author":"Black","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025060208124625800_jiaf088-B8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"2025060208124625800_jiaf088-B9","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1128\/AAC.03233-14","article-title":"1,4-Azaindole, a potential drug candidate for treatment of tuberculosis","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B10","doi-asserted-by":"crossref","first-page":"e02020-19","DOI":"10.1128\/AAC.02020-19","article-title":"OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor","volume":"64","author":"Hariguchi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol Med"},{"key":"2025060208124625800_jiaf088-B12","doi-asserted-by":"crossref","first-page":"e0058321","DOI":"10.1128\/AAC.00583-21","article-title":"Comparative analysis of pharmacodynamics in the C3HeB\/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832","volume":"65","author":"Robertson","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B13","doi-asserted-by":"crossref","first-page":"e0059723","DOI":"10.1128\/aac.00597-23","article-title":"Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB\/FeJ mouse tuberculosis model","volume":"67","author":"Ramey","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B14"},{"key":"2025060208124625800_jiaf088-B15","doi-asserted-by":"crossref","first-page":"2300165","DOI":"10.1183\/13993003.00165-2023","article-title":"Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs","volume":"62","author":"Ernest","year":"2023","journal-title":"Eur Respir J"},{"key":"2025060208124625800_jiaf088-B16","author":"R\u00f6mpp"},{"key":"2025060208124625800_jiaf088-B17","author":"Heinrich"},{"key":"2025060208124625800_jiaf088-B18","author":"Koele"},{"key":"2025060208124625800_jiaf088-B19","doi-asserted-by":"crossref","first-page":"e01727","DOI":"10.1128\/AAC.01727-19","article-title":"Mechanistic modeling of Mycobacterium tuberculosis infection in murine models for drug and vaccine efficacy studies","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B20","author":"ICON, plc"},{"key":"2025060208124625800_jiaf088-B21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"2025060208124625800_jiaf088-B22","author":"R Foundation"},{"key":"2025060208124625800_jiaf088-B23","doi-asserted-by":"crossref","first-page":"e01438-22","DOI":"10.1128\/aac.01438-22","article-title":"Pharmacokinetics and efficacy of the benzothiazinone BTZ-043 against tuberculous mycobacteria inside granulomas in the guinea pig model","volume":"67","author":"Eckhardt","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B24","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","article-title":"Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen","volume":"15","author":"Strydom","year":"2024","journal-title":"Nat Commun"},{"key":"2025060208124625800_jiaf088-B25","first-page":"305","article-title":"Drug interaction studies during drug development: which, when, how?","volume":"32","author":"Kuhlmann","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025060208124625800_jiaf088-B26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/00498250802653758","article-title":"Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?","volume":"39","author":"Srinivas","year":"2009","journal-title":"Xenobiotica"},{"key":"2025060208124625800_jiaf088-B27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00545976","article-title":"Michaelis-Menten absorption kinetics in drugs: examples and implications","volume":"23","author":"Wood","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"2025060208124625800_jiaf088-B28","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060208124625800_jiaf088-B29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1242\/dmm.019570","article-title":"Presence of multiple lesion types with vastly different microenvironments in C3HeB\/FeJ mice following aerosol infection with Mycobacterium tuberculosis","volume":"8","author":"Irwin","year":"2015","journal-title":"Dis Model Mech"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf088\/61905369\/jiaf088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/e901\/61905369\/jiaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/5\/e901\/61905369\/jiaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:12:57Z","timestamp":1748866377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/5\/e901\/8016390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf088","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2025,2,17]]}}}